Genome-wide association study of response to cognitive–behavioural therapy in children with anxiety disorders

Coleman, Jonathan R I, Lester, Kathryn J, Keers, Robert, Roberts, Susanna, Curtis, Charles, Arendt, Kristian, Bögels, Susan, Cooper, Peter, Creswell, Cathy, Dalgleish, Tim, Hartman, Catharina A, Heiervang, Einar R, Hötzel, Katrin, Hudson, Jennifer L., In-Albon, Tina, Lavallee, Kristen, Lyneham, Heidi J, Marin, Carla E, Meiser-Stedman, Richard, Morris, Talia, Nauta, Maaike H., Rapee, Ronald M, Schneider, Silvia, Schneider, Sophie C, Silverman, Wendy K, Thastum, Mikael, Thirlwall, Kerstin, Waite, Polly, Wergeland, Gro Janne, Breen, Gerome and Eley, Thalia C (2016) Genome-wide association study of response to cognitive–behavioural therapy in children with anxiety disorders. The British Journal of Psychiatry, 209 (3). pp. 236-243. ISSN 1472-1465

[img]
Preview
PDF (Coleman ea 2016 IN PRESS VERSION, BJP) - Published Version
Available under License Creative Commons Attribution.

Download (2MB) | Preview

Abstract

Background: Anxiety disorders are common, and cognitive–behavioural therapy (CBT) is a first-line treatment. Candidate gene studies have suggested a genetic basis to treatment response, but findings have been inconsistent. Aims: To perform the first genome-wide association study (GWAS) of psychological treatment response in children with anxiety disorders (n = 980). Method: Presence and severity of anxiety was assessed using semi-structured interview at baseline, on completion of treatment (post-treatment), and 3 to 12 months after treatment completion (follow-up). DNA was genotyped using the Illumina Human Core Exome-12v1.0 array. Linear mixed models were used to test associations between genetic variants and response (change in symptom severity) immediately post-treatment and at 6-month follow-up. Results: No variants passed a genome-wide significance threshold (P = 5×10−8) in either analysis. Four variants met criteria for suggestive significance (P<5×10−6) in association with response post-treatment, and three variants in the 6-month follow-up analysis. Conclusions: This is the first genome-wide therapygenetic study. It suggests no common variants of very high effect underlie response to CBT. Future investigations should maximise power to detect single-variant and polygenic effects by using larger, more homogeneous cohorts.

Item Type: Article
Additional Information: © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) licence.
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 22 Mar 2016 09:17
Last Modified: 17 Mar 2020 21:20
URI: https://ueaeprints.uea.ac.uk/id/eprint/57699
DOI: 10.1192/bjp.bp.115.168229

Actions (login required)

View Item View Item